Phase 3 Voyage 2 study demonstrates sustained response over 5 years with guselkumab for moderate to severe plaque psoriasis (PsO)

At week 252, 55.5% of the guselkumab group achieved an Investigator's Global Assessment (IGA)d score of 0, indicating complete skin clearance, and 53% achieved a Psoriasis Area Severity Index (PASI) ie 100 skin clearance response (PASI 100).

Source:

Biospace Inc.